PathAI
Pathology transformed — AI-powered diagnostics that improve patient outcomes.
Overview
PathAI's strength is its track record: it's used by roughly 90% of the top 15 pharmaceutical companies, and its AISight Dx platform has actual FDA clearance for primary diagnostic use, which is a high bar in medical AI. For biopharma R&D teams, reference labs, and academic medical centers looking to speed up and standardize pathology review, PathAI offers a mature, clinically validated option rather than an unproven startup pitch.
The honest limitation is accessibility — this is enterprise software sold through direct sales conversations, with no listed pricing and no way for an individual pathologist or small clinic to just sign up and test it. Readers should understand PathAI as an institutional infrastructure decision, best compared to other digital pathology platforms serving pharma and hospital systems rather than to consumer AI tools.
Key Features
AISight Digital Pathology Platform: Cloud-native image management system for viewing, sharing, and analyzing pathology slides.
AISight Dx: FDA-cleared platform enabling AI-assisted primary diagnosis directly from digital slides.
AIM Biomarker Algorithms: AI models for quantifying biomarkers such as PD-L1, HER2, ER/PR, and Ki67 used in cancer diagnosis and drug development.
Condition-Specific Modules: Specialized tools like LiverExplore and IBDExplore for disease-specific tissue analysis.
Biopharma Research Support: Used by the majority of top pharmaceutical companies to support clinical trial pathology and drug development.
Pricing
Starting price
Custom pricing only, contact sales
Enterprise/Institutional: Pricing is fully custom, based on lab size, algorithm licenses, and deployment scope; not published publicly.
Disclaimer: pricing may change, confirm on PathAI's own site or by contacting their sales team before buying.
Pros
FDA-Cleared Diagnostics: AISight Dx has regulatory clearance for primary diagnosis, a meaningful credibility marker in clinical AI.
Strong Pharma Adoption: Used by the vast majority of top pharmaceutical companies, showing real market traction.
Broad Biomarker Coverage: Multiple validated algorithms across cancer, liver disease, and IBD reduce reliance on manual scoring.
Cloud-Native Workflow: AISight enables remote and collaborative slide review, useful for distributed pathology teams.
Cons
No Public Pricing: All pricing is negotiated directly with the sales team; nothing is published.
Enterprise-Only Access: No self-serve trial or individual-tier option; it's built for institutions, not solo practitioners.
Integration Overhead: Deploying digital pathology and AI tools into existing lab workflows requires significant IT and validation work.
What Makes It Unique
Unique Angle: PathAI combines an FDA-cleared primary diagnosis platform with a deep bench of biopharma-grade biomarker algorithms, bridging both clinical diagnosis and drug development use cases in one platform.
Kay Score
7.5
/ 10
